Abcam, ab300462, Anti-TREM1 antibody [EPR26206-72] (BSA and Azide free)

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TREM1 antibody. Carrier free. Suitable for ICC/IF, Flow Cyt and reacts with Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR26206-72,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse,
Applications:ICC/IF, Flow CytSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab300462 is a carrier free version of
ab300461
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Triggering receptor expressed on myeloid cells 1 (TREM1) is a transmembrane receptor involved in amplifying inflammatory responses. TREM1 is known alternatively as CD354. This protein has a molecular mass of approximately 30 kDa and is expressed on the surface of neutrophils monocytes and macrophages. The receptor participates in innate immune responses and acts as an amplifier for inflammatory signals. It is often found in tissues that are engaged in inflammatory processes including lungs and intestines.
Biological function summary
TREM1 significantly enhances the immune response by activating myeloid cells. It does not form a standalone unit; instead it works with the adapter protein DNAX-activating protein of 12 kDa (DAP12) which pairs with TREM1 to transduce signals that promote cytokine and chemokine release. Through this interaction the receptor plays a role in the defense against bacterial infection boosting the body's immune response during pathogen assault. This function positions TREM1 as an important player in the regulation of acute inflammation.
Pathways
TREM1 engages significantly in the Toll-like receptor (TLR) signaling pathway and NF-kB pathway. In these pathways TREM1 interacts with various proteins that include TLRs and DAP12 intensifying inflammatory responses. The integration of TREM1 within these pathways suggests that it acts as an important modulator of inflammation capable of enhancing TLR-mediated signals for a stronger immune response.
TREM1 connections extend to sepsis and inflammatory bowel disease (IBD). In the context of sepsis TREM1 expression correlates with increased inflammation and poor prognosis where it interacts with proteins involved in inflammatory pathways such as TNF-α. Concerning IBD TREM1's role in promoting inflammation links it to the pathogenesis of this disease where it could influence the severity and progression of IBD-related inflammation. Given these relationships therapeutic strategies targeting TREM1 could hold potential in modulating these conditions.